Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E. Sands, Olga Fedorishina, Peter M. Irving et al.|The Lancet|2022Cited by 295
Developing in vitro expanded CD45RA<sup>+</sup>regulatory T cells as an adoptive cell therapy for Crohn's diseaseJames B. Canavan, Graham M. Lord, Jonathan W. Lo et al.|Gut|2015Cited by 194
Regulatory T-cell therapy in Crohn’s disease: challenges and advancesJennifer Clough, Peter M. Irving|Gut|2020Cited by 159
Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibilityAleksejs Sazonovs, Peter M. Irving, Christine Stevens et al.|medRxiv|2021Cited by 11